Biodexa Pharmaceuticals Plc ADR Dossier
Qualitative Analysis
Business overview
Biodexa Pharmaceuticals Plc (NASDAQ: BDRX) is a clinical-stage biopharmaceutical company focused on developing innovative products for the treatment of diseases with high unmet medical needs, primarily targeting gastrointestinal cancers, Familial Adenomatous Polyposis (FAP), and Type 1 diabetes. The company's lead development program is eRapa, a proprietary oral capsule formulation of rapamycin (sirolimus) designed as an mTOR inhibitor. eRapa is currently being readied for a Phase 3 registration study (the Serenta study) in FAP, a rare and serious genetic condition that leads to colorectal cancer if untreated. Additionally, Biodexa is developing MTX240, a molecular glue targeting Gastrointestinal Stromal Tumors (GIST), and tolimidone, a selective Lyn kinase inhibitor for Type 1 diabetes. The company has transitioned from a drug delivery technology platform to a therapeutics-focused developer.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Launched a global Early Access Program (EAP) / Named Patient Program to provide eRapa to patients with Familial Adenomatous Polyposis (FAP) who have limited treatment options.
Expected impact: Expands global access to eRapa prior to commercial approval, addressing high unmet medical needs in FAP.
Partnered with Syngene International to manufacture GMP clinical trial supplies for MTX240.
Expected impact: Secures the clinical supply chain for the upcoming Phase 1b/2a clinical trials of MTX240.
Proposed a capital reorganization involving a 10,000:1 reverse split of ordinary shares and adjustments to the ordinary share-to-ADS ratio to simplify the capital structure and maintain Nasdaq listing compliance.
Expected impact: Reduces the exceptionally large number of outstanding ordinary shares and stabilizes the trading price of the ADSs.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
In-licensed MTX240 (formerly OPB-171775), a Phase 1-ready molecular glue targeting GIST, significantly expanding Biodexa's GI oncology pipeline.
Terms: Exclusive worldwide license (excluding Japan and certain other territories) in exchange for upfront and milestone payments.
Facilitates the launch and management of the Global Early Access Program for eRapa in FAP patients.
Terms: Not publicly disclosed.
Provides contract development and manufacturing services to produce GMP-grade clinical trial supplies of MTX240.
Terms: Not publicly disclosed.